Rare diseases
Investigational molecules
Locations
THYTREG is an investigational cell therapy. It consists of autologous regulatory T cells (Tregs) that are differentiated from a child's own thymic tissue, expanded, and stimulated with interleukin-2 (IL-2). The cells are prepared as a solution for infusion and given intravenously. The product is supplied by Fundación para la Investigación Biomédica del Hospital Gregorio Marañón. THYTREG has no marketing authorisation in the product records and remains an experimental substance.[1]
Regulatory T cells are a type of immune cell that helps control the immune system and prevent it from attacking the body's own tissues. In heart transplantation, the recipient's immune system can recognise the donor heart as foreign and attack it, causing rejection. THYTREG is designed to increase the number of Treg cells in the patient, which may help restore the balance between regulatory T cells and effector T cells. This balance is measured as the Treg / T-effector cell ratio. The trial's primary outcome is the repopulation of Treg cells in the patient, determined as the increase of their blood values and the recovery of this ratio compared to values before transplantation.[1]
THYTREG is prepared as a solution for infusion and is administered intravenously. The cells are obtained from the child's own thymus tissue, which is typically removed during cardiac surgery in young children. The tissue is processed to isolate and expand the regulatory T cells before they are given back to the patient.[1]
One clinical trial is registered for THYTREG. It is a Phase 1/2, randomised, exploratory and prospective trial. The trial is authorised and plans to enrol 11 children who have received a heart transplant. The main objective is to evaluate the feasibility, safety and efficacy of infusing autologous thyTreg cells in preventing acute rejection. The primary outcome measures the repopulation of Treg cells in the blood and the recovery of the Treg / T-effector cell ratio compared to pre-transplant values.[1]
The trial is interventional and randomised, meaning participants are assigned to different groups. The study is exploratory and prospective, following participants over time. It is registered in the EU Clinical Trials Information System with the identifier 2024-519845-30-00.[1]
No side effect information is available from the provided sources.
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
